Key Takeaways MRK begins three phase IIb studies of tulisokibart in HS, r-axSpA and rheumatoid arthritis.Tulisokibart is now being tested across six types of immune-mediated inflammatory diseases.MRK's phase III pipeline has nearly tripled since 2021, boosting long-term growth potential.Merck (MRK) announced that it has initiated three separate phase IIb studies evaluating its investigational TL1A inhibitor, tulisokibart (MK-7240), in three new immune-mediated inflammatory diseases.The three new phase IIb s ...

Oct 6, 2025 6:45 AM Eastern Daylight Time Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn's disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and rheumatoid arthritis RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK- 7240), an investigati ...